CHAPTER 64E-5

The PBAC noted that compared to etanercept in the FIXTURE trial, of those patients who were PASI 75 responders at week 12, a statistically significantly greater proportion of patients treated with secukinumab 300 mg (84.3%) compared with etanercept 100 mg/week (72.5%), maintained a PASI 75 … ................
................